Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model

Breast Cancer Research and Treatment

Volumn 142, Issue 1, 2013, Pages 9-18

  Ripoll, Giselle V ^a   Garona, Juan ^a   Pifano, Marina ^a   Farina, Hernan G ^a   Gomez, Daniel E ^a   Alonso, Daniel F ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

Angiostatin; Mammary carcinoma; Mice; Peptide analog; Tumor vascularization; Vasopressin

Indexed keywords

ANGIOSTATIN; DESMOPRESSIN; PLASMINOGEN; UROKINASE; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BREAST CARCINOMA; CANCER CELL CULTURE; CAPILLARY TUBE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; WESTERN BLOTTING; ZYMOGRAPHY;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DEAMINO ARGININE VASOPRESSIN; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEOLYSIS; RECEPTORS, VASOPRESSIN; TUMOR BURDEN;

EID: 84888245087     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2724-6     Document Type: Article

References (28)

1. Zaoral M, Kole J, Sorm F (1967) Synthesis of 1-deamino-8-d-amino-butyrine vasopressin, 1-deamino-8-d-lysine vasopressin and 1-deamino-8-d-arginine vasopressin. Collect Czechoslov Chem Commun 32:1250-1257
2. Birnbaumer M (2000) Vasopressin receptors. Trends Endocrinol Metab 11:406-410
3. Mannucci PM (1997) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 90:2515-2521
4. Kaufmann JE, Vischer UM (2003) Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 1:682-689
5. North WG, Pai S, Friedmann A, Yu X, Fay M, Memoli V (1995) Vasopressin gene related products are markers of human breast cancer. Breast Cancer Res Treat 34:229-235
6. Petit T, Davidson KK, Lawrence RA, von Hoff DD, Izbicka E (2001) Neuropeptide receptor status in human tumor cell lines. Anticancer Drugs 12:133-136
7. North WG, Fay MJ, Du J (1999) MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R. Peptides 20:837-842
8. Keegan BP, Akerman BL, Pequeux C, North WG (2006) Provasopressin expression by breast cancer cells: implications for growth and novel treatment strategies. Breast Cancer Res Treat 95:265-277
9. Taylor AH, Ang VT, Jenkins J, Silverlights RC, Coombes RC, Luqmani YA (1990) Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res 50:7882-7886
10. Alonso DF, Skilton G, Farias EF, de Kier Bal, Joffe E, Gomez DE (1999) Antimetastatic effect of desmopressin in a mouse mammary tumor model. Breast Cancer Res Treat 57:271-275
11. Giron S, Tejera AM, Ripoll GV, Gomez DE, Alonso DF (2002) Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation. J Surg Oncol 81:38-44
12. Hermo GA, Torres P, Ripoll GV, Scursoni AM, Gomez DE, Alonso DF, Gobello C (2008) Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: a pilot study. Vet J 178:103-108
13. Hermo GA, Turic E, Angelico D, Scursoni AM, Gomez DE, Gobello C, Alonso DF (2011) Effect of adjuvant perioperative desmopressin in locally-advanced canine mammary carcinoma and its relation to histological grade. J Am Anim Hosp Assoc 47:21-27
14. Ripoll GV, Giron S, Krzymuski MJ, Hermo GA, Gomez DE, Alonso DF (2008) Antitumor effects of desmopressin in combination with chemotherapeutic agents in a mouse model of breast cancer. Anticancer Res 28:2607-2612
15. Alonso DF, Ripoll GV, Garona J, Iannucci NB, Gomez DE (2011) Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr Pharm Biotechnol 12:1974-1980
16. Wu JM, Staton CA (2012) Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. Expert Opin Drug Discov 7:723-743
17. Folkman J (1971) Tumor angiogenesis: therapeutic implications. New Engl J Med 285:1182-1186
18. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328
19. Westphal JR, Van't Hullenaar R, Geurts-Moespot A, Sweep FC, Verheijen JH, Bussemakers MM, Askaa J, Clemmensen I, Eggermont AA, Ruiter DJ, De Waal RM (2000) Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer 15:760-767
20. Sakurai T, Kudo M (2011) Signaling pathways governing tumor angiogenesis. Oncology 81(Suppl 1):24-29
21. Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM (2000) Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Investig 106:107-116
22. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA (1997) The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci 94:10868-10872
23. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407
24. Sim BK (1998) Angiostatin and endostatin: endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth. Angiogenesis 2:37-48
25. Kaufman JE, Vischer UM (2003) Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 1:682-689
26. Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, Payne EM, Haskard DO, Hughes AD, Cutler DF, Laffan MA, Randi AM (2011) Endothelial von Willebrand factor regulates angiogenesis. Blood 117:1071-1080
27. Zompra AA, Galanis AS, Werbitzky O, Albericio F (2009) Manufacturing peptides as active pharmaceutical ingredients. Future Med Chem 1:361-377
28. Iannucci NB, Ripoll GV, Garona J, Cascone O, Ciccia GN, Gomez DE, Alonso DF (2011) Antiproliferative effect of 1-deamino-8-d-arginine vasopressin analogs on human breast cancer cells. Future Med Chem 3:1987-1993